Track topics on Twitter Track topics that are important to you
Prof Ledermann speaks with ecancer at BCGS 2018 about results from ASCO 2018, highlighting trials of pembrolizumab in relapsed ovarian cancer. He considers the results from these trials, and how the mixed results of KEYNOTE 100 could be lead to the...
Original Article: ASCO highlights: KEYNOTE100NEXT ARTICLE
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...